In preclinical models of NASH-related hepatocellular carcinoma, anti-PD1 treatment leads to more and larger tumor nodules, which are linked to an increase in CD8+PD1+CXCR6+TOX+TNF+ T cells (189). Here, PDCD1 is linked to metabolic dysfunction-associated steatohepatitis.